BEDFORD, Mass., April 20, 2017 – Homology Medicines, Inc., a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients, announced today that its Chief Executive Officer, Arthur Tzianabos, Ph.D., will be presenting at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017 at The State Room in Boston, Massachusetts.
Dr. Tzianabos will deliver a Company presentation at 8:55 a.m. ET, and he will also participate in the panel, “Gene Therapy: Commercialization Readiness & Market Access Challenges,” at 1:30 p.m. ET.
About Homology Medicines, Inc.
Homology Medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The combination of a new multidimensional technology platform and a management team that has successfully developed and commercialized rare disease therapies uniquely positions the Company to move beyond the current limitations of gene therapy and gene editing approaches to improve patient care. Homology Medicines has built foundational intellectual property on gene editing and gene therapy using vectors derived from naturally occurring human adeno-associated viruses (AAVs). The Company’s technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. The unique team and technology create a significant opportunity for Homology Medicines to rapidly advance a diverse pipeline of new medicines that address and potentially cure the underlying cause of genetic diseases. For more information, please visit www.homologymedicines.com.